TAS4464

TAS4464
  • CAS No.:1848959-10-3
  • Grade:98.69%
  • Formula:C21H23FN6O6S
  • M.W.:506.51
  • Solvent:≥ 2 mg/mL (3.95 mM); Clear solution

Important Notice

  1. This product is a chemical product/pharmaceutical intermediate. It is not a drug, an active pharmaceutical ingredient (API), or a pharmaceutical-grade material. It has not been granted a drug approval number or a Chemical Drug Substance Approval Notice, has not passed drug-related review and approval, and is not manufactured, tested, or released in accordance with pharmaceutical GMP.
  2. This product is intended solely for non-clinical research, process development, quality studies, further chemical processing, or chemical synthesis. It must not be used in drug-product manufacturing, clinical trials, clinical diagnosis, or administration to humans or animals, or be sold, used as an input, submitted for regulatory filing, or released as an API or pharmaceutical material.
  3. The purchaser must not use this product, or supply it to another party, for personal consumption, sports or fitness, weight loss, health supplements, food, or animal feed.

Overview

TAS4464 is a long-acting, highly selective covalent inhibitor targeting NEDD8 -activating enzyme ( NAE ) ( IC 50 =0.955 nM), and also inhibits CAII with an IC 50 of 0.73 μM, which is less potent than MLN4924 ( HY-70062 ). The IC 50 values of TAS4464 against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 targets NEDD8 in an ATP-dependent manner to inhibit NAE , blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα ), and further induces tumor cell apoptosis . TAS4464 exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 has a wide selcetive window, without obvious toxicity. TAS4464 can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer , colorectal cancer , sarcoma, endometrial cancer , ovarian cancer , etc.).

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Carbonic Anhydrase | Products > Signaling Pathways > NEDD8-activating Enzyme

Product Information

  • Catalog No.: HY-128586
  • CAS No.: 1848959-10-3
  • Molecular Formula: C21H23FN6O6S
  • Molecular Weight: 506.51
  • Purity: 98.69%
  • Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
  • Solubility: ≥ 2 mg/mL (3.95 mM); Clear solution
  • Availability: In-stock

Source

Original product source


Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Read the full Disclaimer
Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye